5 completed, 2 recruiting, 1 active not recruiting, 1 available. 4 Phase 1, 3 Phase 3, 1 Phase 2.
By phase and status
Follow olpasiran: new trials by email Literature Review of olpasiran trials Research Report on olpasiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial Olpasiran, Placebo - Cardiovascular Disease Phase 3 Recruiting 406 2026-03-23 2026-04-16 OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events Olpasiran, Placebo - Cardiovascular Disease Phase 3 Recruiting 11000 2025-08-22 2026-08-21 A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants Placebo, Olpasiran, Moxifloxacin - Basic Science Phase 1 Completed 32 2024-09-12 2026-10-23 Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial Placebo, Olpasiran - Atherosclerotic Cardiovascular Disease Phase 3 Active not recruiting 7297 2022-12-14 2026-10-27 A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment Olpasiran - Renal Impairment Phase 1 Completed 33 2022-09-13 2026-10-23 A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment Olpasiran - Hepatic Impairment Phase 1 Completed 25 2022-09-13 2026-10-28 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a) Olpasiran - Elevated Serum Lipoprotein(a) Phase 1 Completed 24 2021-07-28 2025-02-10 Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study Olpasiran, Placebo - Cardiovascular Disease Phase 2 Completed 281 2020-07-28 2026-03-31 Olpasiran Expanded Access Program Olpasiran Available 2025-07-23
Conditions studied Cardiovascular Diseases (3) · Atherosclerosis (2) · Coronary Disease (1) · Dyslipidemias (1) · Hyperlipidemias (1) · Myocardial Infarction (1) · Renal Insufficiency (1)
Sponsors Amgen (9)
Countries United States (6) · Australia (4) · Canada (3) · Japan (3) · China (2) · Denmark (2) · France (2) · Germany (2) · Hong Kong (2) · Iceland (2) · Italy (2) · Netherlands (2) · Spain (2) · Austria (1) · Brazil (1)
Results publications PMID 38415744 , PMID 38682459 , PMID 39322524 , PMID 39329200 , PMID 41329869 , PMID 41841810
NIH funding 2019 (1)